Skip to main content
TipRanks
Go Ultimate75% OFF

Embecta Corporation (EMBC) Q3 2026 Earnings Report

122 Followers

EMBC Q3 2026 EPS Results

Actual EPS
$0.56
Consensus EPS
$0.27
Beat/Miss
Beat by +$0.29
One Year Ago EPS
$1.12

EMBC Q3 2026 Revenue Results

Actual Revenue
$271.70M
Expected Revenue
$254.53M
Beat/Miss
Beat by +$17.17M
YoY Revenue Growth
-8.05%

Earnings Announcement Details

Quarter
Q3 2026
Date
08/07/2026
Time
Before Open
Conference Call
Friday, August 7, 2026
EMBC Upcoming Earnings

Embecta Corporation's next earnings date is estimated for December 1, 2026, based on past reporting schedules.

Q3 2026 Earnings Call Audio

EMBC Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Aug 07, 2026|% Change Since:84.14%|
Earnings Call Sentiment|Neutral

The call presents a mixed picture: significant strategic progress (Owen Mumford acquisition expanding TAM, international growth, sequential operational improvement, margin/earnings guidance upgrades, brand transition and organizational reinforcements) offset by sizable year‑over‑year declines in U.S. revenue, gross profit and operating profit, pen needle headwinds, and macro volume pressures. Management emphasized execution, cost controls, and deleveraging while reaffirming revenue guidance and raising margin and EPS targets, resulting in cautious optimism but clear near‑term financial challenges.

Company Guidance

Embecta reaffirmed full‑year fiscal 2026 revenue guidance of $1.015–$1.035 billion (a y/y decline of ~4.2%–6.1%), raised adjusted operating margin guidance to 23.5%–24% (from 22.25%–23.25%) and raised adjusted EPS to $1.80–$1.90 (from $1.55–$1.75), while forecasting FX to be a ~1.3% tailwind (vs. prior ~1.5%), an adjusted tax rate of ~27% (vs. ~28% prior), interest expense of ~$95 million (vs. ~$97M prior), and a weighted average diluted share count of ~58.6 million (vs. ~59.4M prior) — guidance also assumes at least $150 million of debt repayment in 2026 (about $128M repaid in the first 9 months), roughly $100 million of free cash flow, and ~$18–$20 million of capital expenditures (mostly in Q4); management raised M&A expectations for Owen Mumford given the deal closed two weeks earlier and noted adjusted organic constant‑currency assumptions with the high end modestly lowered due to U.S. customer/payer mix.

  • Owen Mumford Acquisition and Strategic ExpansionClosed acquisition of Owen Mumford on May 15; integration progressing as planned. Expands product portfolio beyond insulin devices into pharmaceutical services and auto-injectors (Aidaptus). Management estimates total addressable auto-injector market ≈ $2.4B with double-digit CAGR. Added 4 sites (3 manufacturing: 2 UK, 1 Malaysia; 1 U.S. warehouse) to broaden manufacturing/distribution footprint.
  • Sequential Improvement in Q3 PerformanceSequential vs Q2: total revenue improved by approximately $50M; GAAP operating income improved ≈ $14M; adjusted operating income improved ≈ $21M. Q3 adjusted gross profit improved ≈ $26M sequentially, driven by improved U.S. and International performance and initial Owen Mumford contribution.
  • International StrengthInternational revenue in Q3 ≈ $151M, up 11.5% reported and up 9.7% on an adjusted constant currency basis, driven by Latin America and Asia and contribution from Owen Mumford.
  • Margin and EPS Guidance UpsideRaised adjusted operating margin guidance from 22.25-23.25% to 23.5-24.0%. Raised adjusted EPS guidance from $1.55-1.75 to $1.80-1.90, driven by operating expense controls and cost optimization initiatives.
  • Cash Generation and Deleveraging ProgressGenerated approximately $41M in free cash flow in Q3. Repaid ~ $53M of debt in the quarter and ~ $128M through first 9 months of 2026; expect to repay at least $150M in 2026. Last-12-month net leverage ≈ 3.7x (below covenant requirement of 4.75x). Amended and extended revolving credit facility through December 30, 2028.
  • Brand Transition and Commercial WinsCompleted brand transition in key European, Asian, and Latin American markets; >90% of revenue now under the Embecta label and on track to substantially complete global brand transition by end of calendar 2026. Expanded B2B co-packaging momentum with generic GLP-1 launches (Canada, Brazil, South Africa, India) and small-pack launches planned/in-market.
  • Leadership and Organizational MovesAppointed Jeff Mann as President of Pharma Services and Product Management and Chief Legal Officer to lead pharma services organization; hired Nimish Muzumdar as SVP and President, North America to strengthen commercial execution.

EMBC Earnings History

EMBC earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Dec 01, 20262026 (Q4)0.29-0.5――
Aug 07, 20262026 (Q3)0.270.561.12-50.00% (-0.56)
May 05, 20262026 (Q2)0.420.270.7-61.43% (-0.43)
Feb 05, 20262026 (Q1)0.670.710.659.23% (+0.06)
Nov 25, 20252025 (Q4)0.460.500.4511.11% (+0.05)
Aug 08, 20252025 (Q3)0.781.120.7451.35% (+0.38)
May 09, 20252025 (Q2)0.530.700.674.48% (+0.03)
Feb 06, 20252025 (Q1)0.490.650.616.56% (+0.04)
Nov 26, 20242024 (Q4)0.360.450.59-23.73% (-0.14)
Aug 09, 20242024 (Q3)0.460.740.697.25% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed